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Abstract
Purpose—Patients with hormone receptor–negative breast cancer generally do not benefit from
endocrine-targeted therapies. However, a subset with androgen receptor (AR) expression is
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predicted to respond to antiandrogen therapies. This phase II study explored bicalutamide in AR-
positive, estrogen receptor (ER), and progesterone receptor (PgR)-negative metastatic breast
cancer.
Experimental Design—Tumors from patients with ER/PgR-negative advanced breast cancer
were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered
positive]. If either the primary or a metastatic site was positive, patients were eligible to receive
the AR antagonist bicalutamide at a dose of 150 mg daily. Clinical benefit rate (CBR), the primary
endpoint, was defined as the total number of patients who show a complete response (CR), partial
response (PR), or stable disease (SD) > 6 months; secondary endpoints included progression-free
survival (PFS) and toxicity. Correlative studies included measurement of circulating endocrine
markers and IHC surrogates for basal-like breast cancer.
Results—Of 424 patients with ER/PgR-negative breast cancer, 12% tested AR-positive. The 6-
month CBR was19%[95% confidence interval (CI), 7%–39%]for bicalutamide. The median PFS
was 12 weeks (95% CI, 11–22 weeks). Bicalutamide was well-tolerated with no grade 4/5
treatment-related adverse events observed.
Conclusion—AR was expressed in 12% of patients with ER/PgR-negative breast cancer
screened for this trial. The CBR of 19% observed with bicalutamide shows proof of principle for
the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-
negative, AR-positive breast cancer.
Introduction
Estrogen and the estrogen receptor (ER) have been well-recognized and highly effective
targets for the treatment of ER [and progesterone receptor (PgR)]-positive breast cancers.
Yet patients with breast cancer who truly lack expression of the ER and PgR have not
traditionally derived benefit from conventional endocrine therapies such as selective ER
modulators or aromatase inhibitors. For those patients with triple-negative breast cancer
(TNBC), whose tumors also lack overexpression or amplification of HER2, standard
palliative systemic treatment options are limited to cytotoxic chemotherapy agents. Patients
diagnosed with advanced TNBCs may respond initially to chemotherapy but the duration of
response is often short and there is a higher likelihood of visceral metastases, rapidly
progressive disease, and inferior survival outcomes compared to the other subtypes (1–3).
A comprehensive molecular analysis of 99 archived primary breast tumors at Memorial
Sloan-Kettering Cancer Center (MSKCC; New York, NY) previously identified a subset of
ER/PgR-negative cancers that associated with ER (+) tumors and expressed a molecular
profile suggestive of active hormonal signaling without expression of ER or PgR. This
subset represented about 22% of ER/PgR(−) cancers and had a transcription profile that
resembled molecular apocrine or luminal AR (4–7). Further evaluation confirmed the
absence of ER and revealed overexpression of the androgen receptor (AR). The functional
role of AR was established by the AR-dependent, estrogen-independent growth observed in
response to synthetic androgen, estrogen, and ER antagonist exposure using an MDA-
MB-453 cell line representative of this subset of ER/PgR-negative breast cancer (4).
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On the basis of the observations above, we hypothesized that AR inhibition would have
antitumor activity for patients with AR(+) ER/PgR(−) advanced breast cancer. Bicalutamide
is an oral, nonsteroidal, AR antagonist that is approved by the U.S. Food and Drug
Administration for use in combination with luteinizing hormone-releasing hormone (LHRH)
analogs for the treatment of metastatic prostate cancer. Data for the use of antiandrogens
inwomen have been reported from small studies when used as treatment of hirsutism,
polycystic ovarian syndrome, or ovarian cancer in women with elevated ovarian androgen
production at baseline. However, these data about the effect of antiandrogens on circulating
androgens and estrogens are limited and, in one case, confounded by coadministration of an
LHRH agonist (8–11).
We conducted a multicenter phase II, proof-of-concept trial testing bicalutamide for the
treatment of women with AR(+) ER/PgR(−) metastatic breast cancer (MBC). We measured
serial levels of free and total testosterone, estradiol, and sex hormone–binding globulin
(SHBG). Cytokeratin-5/6 and EGF receptor (EGFR) were tested to apply Nielsen criteria as
a surrogate for basal-like breast cancer (12).
Materials and Methods
Study design
This open-label, single-arm study was initially opened at MSKCC and later expanded to 7
additional centers through the Translational Breast Cancer Research Consortium (TBCRC).
The primary objective was to evaluate the efficacy of oral bicalutamide, 150 mg/d for the
treatment of women with AR+ER/PgR-negative MBC. The primary endpoint was clinical
benefit rate (CBR), defined as the total number of patients who show a complete response
(CR), partial response (PR), or stable disease (SD) > 6 months. Secondary endpoints
included progression-free survival (PFS), safety and toxicity assessments, and correlative
science studies. Enrollment required 2 steps: (i) consent to determine AR status, which was
permitted while on another therapy for breast cancer, followed by (ii) consent to the
therapeutic portion of the trial for patients with centrally confirmed AR (+) ER/PgR(−)
MBC.
Patient eligibility
Four hundred and fifty-two patients with histologically confirmed ER/PgR-negative
[immunohistochemistry (IHC) ≤10%] MBC consented for AR testing at participating
TBCRC institutions from March 2007 through January 2012. Patients were eligible for the
therapeutic portion of the trial if they had ER/PgR-negative unresectable locally advanced or
metastatic disease and formalin-fixed, paraffin-embedded tumor from either the primary or a
metastatic site tested positive for AR (IHC > 10% nuclear staining) using a commercially
available antibody (Dako, AR 441; dilution: 1:300). Initially local testing at study sites was
permitted with central confirmation at MSKCC. Nine of 43 patients who elected to have
local AR testing were AR(+) locally. Four of the 9 patients were AR(−) on central testing.
Given this discordance, as of August 2010, all testing was conducted centrally at MSKCC
for standardization of methods.
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Additional eligibility criteria included measurable or nonmeasurable disease per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.0, Eastern Cooperative Oncology
Group performance status < 2, and adequate hepatic, renal, and hematologic function. There
was no limit on prior therapies, except prior trastuzumab was required for patients with
HER2-positive disease (IHC 3+ or FISH > 2.0). Exclusion criteria included chemotherapy
within 2 weeks and investigational therapy within 3 weeks. The institutional review boards
of the participating centers approved this protocol. All patients gave written informed
consent (NCT00468715).
Treatment
Bicalutamide 150 mg was administered orally on a continuous daily schedule. Patients were
treated until disease progression or unacceptable adverse events. A maximum of 2 dose
reductions for grade ≥3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was
permitted for treatment delays due to toxicity.
Patient evaluation
Patients were evaluated for toxicity at the time of each 4-week treatment cycle, according to
the National Cancer Institute Common Toxicity Criteria, version 3.0 (NCI-CTC v3.0).
Radiographic response was evaluated every 12 weeks with radiographic scans that were
reviewed at each site by a designated study radiologist, according to RECIST.
Statistical analysis
This study was designed as a single-stage, phase II which required a total of 28 patients to
discriminate between true CBRs of ≤5% and ≥20% at a type I error of 5% and a type II error
of 16%. If 4 or more patients had a CR, PR, or SD > 6 months, bicalutamide would be
considered to have activity in this patient population and would merit further clinical study.
PFS was defined from start of therapy to progression of disease or last date of follow-up and
analyzed using Kaplan–Meier methods. Response rates were calculated with 95% exact
confidence intervals (CI). Toxicities were summarized using NCI-CTC v3.0, and the
maximum grade per patient was used as the summary measure.
Correlative studies
Peripheral blood was obtained at baseline, start of cycle 2 (C2) and end of study (EOS) to
measure total and free testosterone (T), estradiol (E), and SHBG using a commercially
available assay. Summary statistics such as mean, median, and proportions were calculated
for these values. Wilcoxon signed-rank test was conducted to compare baseline to C2 and
EOS values. Percent change for each endocrine biomarker from baseline was examined to
account for variations in baseline values.
Unstained slides or tissue blocks representative of malignant AR(+), ER/PR(−) tissue were
stained for CK5/6 (Dako D5/16 B4; dilution 1:200) and EGFR (Invitrogen 31G7; dilution
1:100) using standard immunoperoxidase techniques by the core facility at Memorial Sloan-
Kettering Cancer Center. Staining intensity was reviewed and scored by the study
pathologist as follows: percent cells staining and the intensity of staining (0, no staining; 1+,
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mild; 2+, moderate; and 3+, strong intensity). Data will be presented in tabular form and
analysis is primarily exploratory and hypothesis generating.
Results
Patient demographics
Twelve percent (51 of 424) of screened patients tested AR (+). Fewer than 10 of the patients
who tested negative for AR expression had staining in the range from 1% to 10% by IHC.
Thirty-two of the 424 patient samples tested were HER2-positive (7.5%) and 7 were positive
for both AR and HER2. Of the 452 patients consented for testing, 28 did not undergo testing
as they had either insufficient tissue (n = 17), tested ER(+) (n = 4), died before testing (n =
2), withdrew consent (n = 3), consented after the close of trial (n = 1), or did not have
confirmed metastatic disease (n = 1). Eight patients whose tumors tested AR+ were
ineligible for treatment due to testing ER(+) centrally (2), developing a second primary
cancer (1), not meeting all of the prespecified eligibility criteria (2), or having a significant
decline in performance status (3). Fifteen patients were eligible for bicalutamide but
continued on effective treatment and thus were not enrolled on the therapeutic portion of the
trial before it reached its accrual goal. Twenty-eight patients were treated on study (Fig. 1).
Two patients who initiated bicalutamide were later found to be ER(+) and were removed
from study—one at the time of PD and the other at the time of central confirmation. Patient
characteristics are shown in Table 1. Study participants had a median age of 66 years (range,
41–83) and ECOG performance status (median, 0; range, 0–1). The majority had visceral
metastases and received a median of 1 (0–8) prior line of chemotherapy for metastatic
disease.
Efficacy
Twenty-six study participants with AR(+) ER/PgR(−) MBC were evaluable for the primary
endpoint. Five patients had stable disease >6 months (number of cycles completed: 6, 8,
10+, 13, 57+) as their best response on treatment. There were no confirmed complete or
partial responses yielding a CBR of 19% (95% CI, 7%–39%) in the target population (n =
26). In an intention-to-treat analysis, a CBR of 18% (95% CI, 6%–37%) was observed. One
patient with unresectable, locally advanced, ER/PgR/HER2-negative breast cancer following
neoadjuvant anthracycline- and taxane-based therapy had stable disease per RECIST after 6
months on study but was then able to undergo curative breast surgery. At the time of
mastectomy, she was found to have HER2(+) cancer and subsequently received 1 year of
trastuzumab. Clinicopathologic features of the 5 patients deriving clinical benefit from
therapy are shown in Table 2. Two patients had stable disease < 6 months, and 19 patients
had disease progression as best response. We delivered a median of 3 cycles of therapy (2–
57+) and 2 patients remain on treatment after 57+ and 11+ cycles. Median PFS was 12
weeks (95% CI, 11–22 weeks; Fig. 2).
Adverse events
The most common, possibly drug-related toxicities of any grade were fatigue (6 of 28), hot
flashes (6 of 28), limb edema (6 of 28), aspartate aminotransferase (AST) elevation (7 of
28), and alkaline aminotransferase (ALT) elevation (6 of 28). Grade 1toxicities reported in
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more than 10% of patients on study are shown in Table 3. There were few grade 2 or 3
adverse events associated with bicalutamide (Table 3). All grade 3 liver enzyme
abnormalities (elevation in AST, bilirubin, and alkaline phosphatase) were documented in 1
patient with known liver metastases who had progressed on therapy. Thus, it remains
unclear whether these laboratory findings were attributable to bicalutamide therapy or
disease progression. There were no grade 4 or 5 events or treatment-related serious adverse
events. Two patients had dose delays as a result of grade 2 AST elevations later determined
to be related to disease progression in the liver. One patient had a protocol-stipulated dose
reduction to 100 mg for cerebrovascular ischemia that was later determined to be related to
poorly controlled hypertension rather than study drug; she remains on therapy with stable
disease.
Correlative endpoints
Serum hormone levels—Ninety-two percent of evaluable patients at baseline were
postmenopausal. Evaluable patients were numbered 26, 26, and 19 at baseline, C2, and EOS,
respectively. Median free and total T, E, and SHBG are shown in Supplementary Fig. S1 as
boxplots. Nodiscernible patterns of change in serum hormone levels were observed in
response to bicalutamide therapy. There was no difference in median percent change
observed across time points for each endocrine biomarker examined (Supplementary Table
S1 and Supplementary Fig. S2).
IHC characterization of basal-like breast cancer—Four patients (15%) had
sufficient invasive tumor adequate for correlative IHC following testing of ER, PR, and AR.
The results of CK5/6, EGFR, HER2, and ER staining are shown in Table 4. One of the 4
patients had clinical benefit to bicalutamide and lacked expression of basal-like cytokeratins
and EGFR. Two nonresponders showed expression of both CK5/6 and EGFR, suggestive of
a basal-like subtype rather than an AR-dependent one.
Discussion
On the basis of the results of the screening stage of this trial, AR is expressed in 12% of
patients with ER/PgR-negative breast cancer. Our patient population largely represented
TNBC, with the majority of patients having HER2 normal cancers. In this selected subset of
patients with AR (+) ER/PgR(−) MBC, this study met its prespecified endpoint, showing a
CBR of 19% for bicalutamide 150 mg by mouth daily. This therapy was well-tolerated with
the most common treatment-related adverse events including fatigue, hot flashes, limb
edema, and transaminase elevations.
This is the first clinical trial to report activity of antiandrogen therapy in advanced breast
cancer and establishes the potential of targeting AR in AR-dependent, ER-independent
disease. Previous studies that examined the use of flutamide, an oral antiandrogen, for the
treatment of MBC concluded a lack of meaningful antitumor activity. However, these small
phase II trials were conducted in unselected patient populations irrespective of AR, ER, or
PgR (13, 14).
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Overall, AR is expressed in about 77% of breast cancers and coexpression with ER is
common (15–17). In contrast, the literature suggests expression ofARin about20%to50% of
ER-negative breast cancers (4, 15). This wide range may be attributed to the retrospective
nature of these studies and the biases inherent to this type of analysis, variability in patient
selection from archival specimens (i.e., primary tumors vs. metastases; coexpression of
HER2), differing assays for AR testing, or other factors not yet realized. Our prospective
screening experience in this study of more than 450 patients with ER/PgR(−) cancers found
that about 12% expressed nuclear staining of AR in excess of 10%. The IHC methods on
study used the same commercially available antibody from the preclinical studies that
informed the design of our trial. Although the observed AR rate of 12% is lower than that
previously reported, it is consistent with more recent reports from a triple-negative breast
cancer dataset in which 10% of more than 170 breast cancer primary tumors tested AR(+)
(18).
We observed clinical features in this population of patients with AR(+) ER/PgR(−) breast
cancers that differ from those that typically characterize TNBC. The median age of 66 years
was higher than the mean age at diagnosis for patients with TNBC, which is usually more
than a decade earlier (~53 years of age; ref. 3). Sites of metastases in our study often
included nodal, soft tissue and bone, whereas TNBCs have been noted to have patterns of
spread preferentially to brain, lungs, and other viscera (19–21).
While correlative science studies are ongoing to investigate potential genomic predictors of
response to antiandrogen therapy, we observed that those patients who derived clinical
benefit from bicalutamide received treatment in the first- or second-line setting. All patients
had substantial AR expression, measuring 20% to >90%. One patient who had prolonged
stable disease for >12 months had weak ER expression measuring 3%. At the time of study
accrual, ASCO/CAP guidelines had not yet lowered the threshold defining ER positivity to
its current level of 1% or greater (22). We elected to maintain eligibility criteria as
previously specified due to the recognized heterogeneity within TNBCs. Preclinical cell line
models from Doane and colleagues showed estrogen independence in this molecular
subtype; therefore, the impact of weak ER expression for this 1 patient is unclear. In
addition, recent preclinical data showed that bicalutamide did not inhibit estrogen-mediated
proliferation of ER+ breast cancer cells (23).
Recent reports suggest that TNBCs may be divided into as many as 6 subtypes based on
molecular profiling, 1 of which is defined as luminal AR and marked by hormone-regulated
pathways with expression of higher levels of AR mRNA than the other subtypes (6). We
hypothesized that the absence of basal-like breast cancer IHC markers would predict for
response to antiandrogen therapy as this AR-dependent subtype of breast cancer is distinct
from the basal-like subtypes (BL1 and BL2) described by Lehmann and colleagues (6). Our
findings are consistent with this hypothesis, albeit limited by the small numbers available for
analysis. One patient with prolonged stable disease lacked expression of CK5/6, EGFR, and
HER2, whereas two-thirds of the nonresponders expressed the Nielsen criteria suggestive of
the basal-like subtype.
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One of the patients with response to therapy had unresectable locally advanced ER/PgR(−),
HER2 1–2+/FISH 1.1 breast cancer following neoadjuvant anthracycline and taxane-based
therapy. After 6 months of study treatment, she had tumor reduction sufficient to enable
definitive breast surgery but did not meet RECIST for partial response. At the time of
mastectomy, she was found to have HER2 overexpression (IHC 3+) and went on to receive
1 year of adjuvant trastuzumab off-study. Interestingly, AR expression has been reported in
about 50% to 60% of HER2-positive breast cancers (15, 24–26), and others have found a
significant number of ER(−)/HER2(+) breast tumors that express AR and exhibit androgen-
dependent growth. It has also been shown that androgen stimulates tumor cell growth
through Wnt and HER2 signaling pathways via AR-dependent upregulation of WNT7B and
HER3 (27). Functionally significant cross-talk between AR and HER2 signaling pathways in
ER(−) breast cancer has also been shown in molecular apocrine cell lines by inhibition of
heregulin-mediated growth with the use of flutamide. Synergy with combined use of
flutamide and the anti-ErbB2 AG825 has been shown with respect to cell proliferation and
apoptosis, suggesting a potential clinical advantage to combination therapy for AR(+),
ER(−), HER2(+) breast cancers (28).
Median PFS in this study was 12 weeks, a rate comparable to that reported for single-agent
or combination chemotherapy in multiple recent trials conducted in the triple-negative
population (29–31). The disease stabilization observed in 5 patients on this study is
encouraging and suggests a signal of activity for androgen blockade in AR (+) ER/PgR(−)
breast cancer. However, given the generally aggressive clinical course associated with
TNBCs, these findings may alternatively reflect identification of a more indolent subtype of
the disease characterized by AR expression. This possibility is supported by the observation
that the clinical characteristics of this cohort appeared to differ from the traditional TNBC
clinical features as described above. This remains an area of investigation to be answered by
future trial designs.
This study highlights the challenges of drug development in the era of "precision medicine."
Targets may be rare, responses may not meet criteria per RECIST, and individual centers
may not be able to complete such studies. At the same time, this study is proof of concept
for the use of targeting AR when positive in patients with ER/PgR(−) breast cancers.
Although this subgroup represents a small percentage of all breast cancers (15% of breast
cancers are triple-negative, 12% of these are AR+, meaning that only 2% of all patients have
tumors in this subset), the absolute numbers are nonetheless clinically meaningful. Two
percent of the more than 200,000 women diagnosed with breast cancer in the United States
in 2012 yields 4,000 potential patients (32). For the subset of these who develop metastatic
disease, the opportunity to receive minimally toxic, oral, endocrine therapy with clinical
benefit is a new treatment option.
There are additional challenges to the development of AR targeting agents in women with
MBC. As in other settings, there are no validated biomarkers of response to antiandrogen
therapy. To that point, our exploration of serum hormone levels did not appear to offer use
as a pharmacodynamic marker of bicalutamide activity (33). The full potential of targeting
AR in both ER(−) and ER(+) breast cancers is not yet explored, and the possibility of dual
pathway inhibition of androgen and HER2, MEK, or PI3K/AKT as suggested by preclinical
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trials is unexplored clinically (6, 27, 28, 34, 35). Perhaps equally challenging will be the
feasibility of drug development through conventional randomized phase III trials for the
small population of patients expressing this target. To this end, trials are ongoing to test the
safety and feasibility of next-generation, novel androgen-targeted therapies such as
enzalutamide (NCT01597193) in this patient population, but new regulatory approaches to
establishing their efficacy may be needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Genome-wide transcriptional analysis identified a subset of androgen receptor (AR)
positive, estrogen receptor (ER)/progesterone receptor (PgR)-negative breast cancers. In
vitro studies confirmed the functional role of AR and showed that growth could be
abrogated by antiandrogens. We conducted this multicenter phase II trial of the oral AR
inhibitor bicalutamide in patients with AR(+) ER/PR(−) metastatic breast cancer to test
the hypothesis that androgen blockade could benefit patients with androgen-dependent,
estrogen-independent cancer. This is the first clinical trial to report activity of
antiandrogen therapy in breast cancer and establishes the potential of targeting AR in
ER(−) disease.
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PFS on oral daily bicalutamide 150 mg.
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Table 1
Characteristics of patients with AR(+) tumors
Eligible patients treated
with bicalutamide (N = 26)
Patients not treated with
bicalutamide/ineligible (N = 25)
Characteristics No. of pts (n) No. of pts (n)
ER/PgR
  0% 22 16
  1%–10% 4 5
  >10% NA 4
HER2-positive 1 6
Site of AR testing
  Primary 17 14
  Metastatic 9 11
Median age (range), y 66 (41–83) 58 (30–76)
Median ECOG PS (range) 0 (0–1) NAa
Sites of metastases
  Visceral metastases 15 NAa
  Thoracic/pleural (9), hepatic (8), gastric (1), adrenal (2)
  Bone/soft tissue/lymph node metastases 21 NAa
Measurable 22 NAa
Nonmeasurable 4 NAa
Prior chemotherapy for early-stage breast cancer
  Adjuvant 13 NAa
  Neoadjuvant 7 NAa
Number of patients with de novo MBC 2 NAa
Prior chemotherapy for MBC
  Median number of regimens (range) 1 (0–8) NAa
NOTE: HER2-positive defined as IHC 3+ or FISH > 2.
a
TBCRC011 involved a 2-step enrollment process that allowed patients with ER/PgR(−) breast cancer that was metastatic to be tested for AR
without enrolling in the therapeutic portion of the trial. Therefore, the patients who tested AR-positive but did not consent to therapy did not have
clinical data collected aside from ER, PR, HER2, age, and site of disease tested for AR.























































































































































































































































































































































Gucalp et al. Page 17
Table 3








AST 5 1 1
ALT 5 1
Hyperbilirubinemia 1
Alkaline phosphatase 1 1
Nausea 1
Pain
  Headache, back, other 3
  Breast 3









NOTE: Grade 1 toxicities reported in >10% of patients (n = 28). No grade 4 or 5 events or treatment-related serious adverse events observed.
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